Vanda Pharmaceuticals (VNDA) and Epizyme (EPZM) Head-To-Head Analysis
Vanda Pharmaceuticals (NASDAQ: VNDA) and Epizyme (NASDAQ:EPZM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Risk and Volatility
Vanda Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Epizyme has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.
This is a summary of recent recommendations for Vanda Pharmaceuticals and Epizyme, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Vanda Pharmaceuticals presently has a consensus target price of $22.20, suggesting a potential upside of 53.10%. Epizyme has a consensus target price of $22.67, suggesting a potential upside of 52.64%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Vanda Pharmaceuticals is more favorable than Epizyme.
Earnings and Valuation
This table compares Vanda Pharmaceuticals and Epizyme’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Vanda Pharmaceuticals||$146.02 million||4.46||-$18.01 million||($0.32)||-45.31|
|Epizyme||$8.01 million||128.44||-$110.21 million||($2.27)||-6.54|
Vanda Pharmaceuticals has higher revenue and earnings than Epizyme. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.
This table compares Vanda Pharmaceuticals and Epizyme’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
88.4% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Epizyme shares are owned by institutional investors. 7.6% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 25.2% of Epizyme shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Vanda Pharmaceuticals beats Epizyme on 8 of the 14 factors compared between the two stocks.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company’s lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.